Everolimus in hormone receptor-positive advanced breast cancer: Targeting receptor-based mechanisms of resistance

Breast

Volumn 22, Issue 4, 2013, Pages 405-410

  Shtivelband, Mikhail I ^a  

^a Ironwood Cancer and Research Center   (United States)

Author keywords

Estrogen receptor; Everolimus; Mammalian target of rapamycin; MTOR

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; APITOLISIB; AROMATASE INHIBITOR; AZD 2014; BUPARLISIB; DALOTUZUMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; EVEROLIMUS; EXEMESTANE; FULVESTRANT; HORMONE RECEPTOR; LETROZOLE; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE; PF 04691502; PICTILISIB; PLACEBO; PROGESTERONE RECEPTOR; RIDAFOROLIMUS; SOMATOMEDIN RECEPTOR; TAMOXIFEN; TEMSIROLIMUS; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; XL 147; XL 765;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER HORMONE THERAPY; CANCER RESISTANCE; COMBINATION CHEMOTHERAPY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG POTENTIATION; DRUG RESISTANCE; DRUG RESPONSE; DRUG SENSITIVITY; DRUG TARGETING; DRUG TOLERABILITY; HUMAN; MONOTHERAPY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION;

EID: 84879782716     PISSN: 09609776     EISSN: 15323080     Source Type: Journal    
DOI: 10.1016/j.breast.2013.02.003     Document Type: Review

References (43)

1. American Cancer Society Cancer facts and figures 2012, Atlanta, GA. p. 1-66.
2. Hammond M.E., Hayes D.F., Dowsett M., Allred D.C., Hagerty K.L., Badve S., et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch Pathol Lab Med 2010, 134(7):e48-e72.
3. Harris J.R. Staging of breast cancer. Diseases of the breast 2010, 489-500. Wolters Kluwer/Lippincott Williams & Wilkins, Philadelphia. J.R. Harris (Ed.).
4. Rakha E.A., Reis-Filho J.S., Baehner F., Dabbs D.J., Decker T., Eusebi V., et al. Breast cancer prognostic classification in the molecular era: the role of histological grade. Breast Cancer Res 2010, 12(4):207.
5. Anderson W.F., Chatterjee N., Ershler W.B., Brawley O.W. Estrogen receptor breast cancer phenotypes in the surveillance, epidemiology, and end results database. Breast Cancer Res Treat 2002, 76(1):27-36.
6. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005, 365(9472):1687-1717.
7. Ovarian ablation in early breast cancer: overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 1996, 348(9036):1189-1196. No authors.
8. Cuzick J., Ambroisine L., Davidson N., Jakesz R., Kaufmann M., Regan M., et al. Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials. Lancet 2007, 369(9574):1711-1723. LHRH-agonists in Early Breast Cancer Overview Group.
9. Fisher B., Costantino J.P., Wickerham D.L., Redmond C.K., Kavanah M., Cronin W.M., et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. JNatl Cancer Inst 1998, 90(18):1371-1388.
10. Miller W.R. Biology of aromatase inhibitors: pharmacology/endocrinology within the breast. Endocr Relat Cancer 1999, 6(2):187-195.
11. Howell A. Faslodex (ICI 182780). An oestrogen receptor downregulator. Eur J Cancer 2000, 36(Suppl. 4):S87-S88.
12. Buzdar A.U. Advances in endocrine treatments for postmenopausal women with metastatic and early breast cancer. Oncologist 2003, 8(4):335-341.
13. Osborne C.K., Schiff R. Growth factor receptor cross-talk with estrogen receptor as a mechanism for tamoxifen resistance in breast cancer. Breast 2003, 12(6):362-367.
14. Madaio R.A., Spalletta G., Cravello L., Ceci M., Repetto L., Naso G. Overcoming endocrine resistance in breast cancer. Curr Cancer Drug Targets 2010, 10(5):519-528.
15. Santen R.J., Song R.X., Zhang Z., Kumar R., Jeng M.H., Masamura S., et al. Adaptive hypersensitivity to estrogen: mechanisms and clinical relevance to aromatase inhibitor therapy in breast cancer treatment. JSter Biochem Mol Biol 2005, 95(1-5):155-165.
16. Johnston S.R. Clinical trials of intracellular signal transductions inhibitors for breast cancer - a strategy to overcome endocrine resistance. Endocr Relat Cancer 2005, 12(Suppl. 1):S145-S157.
17. Hay N., Sonenberg N. Upstream and downstream of mTOR. Genes Dev 2004, 18(16):1926-1945.
18. Beevers C.S., Li F., Liu L., Huang S. Curcumin inhibits the mammalian target of rapamycin-mediated signaling pathways in cancer cells. Int J Cancer 2006, 119(4):757-764.
19. Sabatini D.M. mTOR and cancer: insights into a complex relationship. Nat Rev Cancer 2006, 6(9):729-734.
20. Bjornsti M.A., Houghton P.J. The TOR pathway: a target for cancer therapy. Nat Rev Cancer 2004, 4(5):335-348.
21. Carraway H., Hidalgo M. New targets for therapy in breast cancer: mammalian target of rapamycin (mTOR) antagonists. Breast Cancer Res 2004, 6(5):219-224.
22. Chollet P., Abrial C., Tacca O., Mouret-Reynier M.A., Leheurteur M., Durando X., et al. Mammalian target of rapamycin inhibitors in combination with letrozole in breast cancer. Clin Breast Cancer 2006, 7(4):336-338.
23. Berns K., Horlings H.M., Hennessy B.T., Madiredjo M., Hijmans E.M., Beelen K., et al. Afunctional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 2007, 12(4):395-402.
24. Nagata Y., Lan K.H., Zhou X., et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 2004, 6(2):117-127.
25. Sokolosky M.L., Stadelman K.M., Chappell W.H., Abrams S.L., Martelli A.M., Stivala F., et al. Involvement of Akt-1 and mTOR in sensitivity of breast cancer to targeted therapy. Oncotarget 2011, 2(7):538-550.
26. Saal L.H., Holm K., Maurer M., Memeo L., Su T., Wang X., et al. PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res 2005, 65(7):2554-2559.
27. Neshat M.S., Mellinghoff I.K., Tran C., Stiles B., Thomas G., Petersen R., et al. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci U S A 2001, 98(18):10314-10319.
28. Yu K., Toral-Barza L., Discafani C., Zhang W.G., Skotnicki J., Frost P., et al. mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer. Endocr Rel Cancer 2001, 8(3):249-258.
29. Weigelt B., Warne P.H., Downward J. PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs. Oncogene 2011, 30(29):3222-3233.
30. Rudloff J., Boulay A., Zumstein-Mecker S., Evans D.B., O'Reilly T., Lane H.A., et al. The mTOR pathway in estrogen response: a potential for combining the rapamycin derivative RAD001 with the aromatase inhibitor letrozole in breast carcinomas. Proc Am Assoc Cancer Res 2004, 45:A5619.
31. de Graffenried L.A., Fulcher L., Friedrichs W.E., Grunwald V., Ray R.B., Hidalgo M., et al. Reduced PTEN expression in breast cancer cells confers susceptibility to inhibitors of the PI3 kinase/Akt pathway. Ann Oncol 2004, 15(10):1510-1516.
32. Beeram M., Tan Q.T., Tekmal R.R., Russell D., Middleton A., DeGraffenried L.A., et al. Akt-induced endocrine therapy resistance is reversed by inhibition of mTOR signaling. Ann Oncol 2007, 18(8):1323-1328.
33. Boulay A., Rudloff J., Ye J., Zumstein-Mecker S., O'Reilly T., Evans D.B., et al. Dual inhibition of mTOR and estrogen receptor signaling invitro induces cell death in models of breast cancer. Clin Cancer Res 2005, 11(14):5319-5328.
34. Carpenter JT, Roche H, Campone M, etal. Randomized 3-arm, phase 2 study of temsirolimus (CCI-779) in combination with letrozole in postmenopausal women with locally advanced or metastatic breast cancer. Presented at the 2005 ASCO annual meeting, Orlando, FL; May 13-15, 2005.
35. Wolff A.C., Lazar A.A., Bondarenko I., Garin A.M., Brincat S., Chow L., et al. Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer. JClin Oncol 2013, 31(2):195-202.
36. Awada A., Cardoso F., Fontaine C., Dirix L., De Greve J., Sotiriou C., et al. The oral mTOR inhibitor RAD001 (everolimus) in combination with letrozole in patients with advanced breast cancer: results of a phase I study with pharmacokinetics. Eur J Cancer 2008, 44(1):84-91.
37. Baselga J., Campone M., Piccart M., Burris H.A., Rugo H.S., Sahmoud T., et al. Everolimus in postmenopausal hormone receptor-positive advanced breast cancer. NEngl J Med 2012, 366(6):520-529.
38. Hortobagyi GN, Piccart M, Rugo H, etal. Everolimus for postmenopausal women with advanced breast cancer: updated results of the BOLERO 2 phase III trial. Presented at the 34th annual San Antonio breast cancer symposium, San Antonio, TX; December 6-10, 2011.
39. Piccart M, Noguchi S, Pritchard KI, etal. Everolimus for postmenopausal women with advanced breast cancer: updated results of the BOLERO-2 phase III trial. 6-1-2012. Presented at the American Society of Clinical Oncology annual meeting, Chicago, Illinois; June 1-5, 2012.
40. Bachelot T., Bourgier C., Cropet C., Ray-Coquard I., Ferrero J.-M., Freyer G., et al. Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. JClin Oncol 2012, 30:2718-2724.
41. Baselga J., Semiglazov V., van Dam P., Manikhas A., Bellet M., Mayordomo J., et al. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. JClin Oncol 2009, 27(16):2630-2637.
42. Badin F, Romond E, Chambers M, etal. A phase II trial of fulvestrant and RAD001 (everolimus) in patients with metastatic estrogen receptor positive breast cancer after aromatase inhibitor failure; a study in progress. Presented at the 33rd annual San Antonio breast cancer symposium, San Antonio, TX; December 8-12, 2010.
43. Rugo HS, Pritchard KI, Gnant M, etal. Everolimus (EVE) for postmenopausal women with advanced breast cancer (ABC) refractory to letrozole or anastrozole: long-term efficacy and safety results of the BOLERO-2 trial. Presented at the 8th European breast cancer conference, Vienna, Austria; March 21-24, 2012.